Vascular Biogenics Ltd. (VBLT) Rating Reiterated by HC Wainwright
HC Wainwright restated their buy rating on shares of Vascular Biogenics Ltd. (NASDAQ:VBLT) in a research report report published on Tuesday morning. HC Wainwright currently has a $11.00 price objective on the biopharmaceutical company’s stock.
A number of other equities analysts have also issued reports on the stock. Chardan Capital raised their target price on shares of Vascular Biogenics from $20.00 to $25.00 and gave the stock a buy rating in a research report on Monday, November 6th. Zacks Investment Research upgraded shares of Vascular Biogenics from a sell rating to a hold rating in a research report on Wednesday, October 18th. Finally, ValuEngine lowered shares of Vascular Biogenics from a hold rating to a sell rating in a research report on Wednesday, September 27th. One analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the company. Vascular Biogenics has an average rating of Buy and an average price target of $16.00.
Shares of Vascular Biogenics (NASDAQ VBLT) traded up $0.25 on Tuesday, hitting $7.65. 224,200 shares of the stock were exchanged, compared to its average volume of 130,901. Vascular Biogenics has a twelve month low of $3.90 and a twelve month high of $7.70.
Vascular Biogenics (NASDAQ:VBLT) last announced its earnings results on Monday, August 14th. The biopharmaceutical company reported ($0.18) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.01. research analysts predict that Vascular Biogenics will post -0.81 EPS for the current year.
An institutional investor recently bought a new position in Vascular Biogenics stock. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in Vascular Biogenics Ltd. (NASDAQ:VBLT) during the third quarter, according to its most recent filing with the SEC. The firm acquired 22,100 shares of the biopharmaceutical company’s stock, valued at approximately $135,000. Zurcher Kantonalbank Zurich Cantonalbank owned about 0.08% of Vascular Biogenics at the end of the most recent reporting period. 11.17% of the stock is owned by institutional investors and hedge funds.
Vascular Biogenics Company Profile
Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of treatments for cancer. The Company’s program is based on its Vascular Targeting System (VTS) platform technology, which utilizes genetically targeted therapy to destroy newly formed, or angiogenic, blood vessels.
Receive News & Ratings for Vascular Biogenics Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Biogenics Ltd. and related companies with Analyst Ratings Network's FREE daily email newsletter.